Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celladon Corp announces commencement of public offering of common stock


Thursday, 7 Aug 2014 06:30am EDT 

Celladon Corp:Offering to sell 4,000,000 shares of its common stock in an underwritten public offering.In connection with this offering, company grant to underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock.Offering is subject to market conditions, and there can be no assurance as to whether or when offering may be completed, or as to actual size or terms of offering.Using net proceeds to fund research and development activities related to its lead product candidate, MYDICAR, including activities related to seeking regulatory approval for MYDICAR and its companion diagnostic.Proceeds also used for treatment of systolic heart failure and other indications, for development of commercial manufacturing capabilities, and for working capital and general corporate purposes. 

Company Quote

18.61
0.06 +0.32%
19 Dec 2014